This case illustrates an unusual presentation of LCNEC, initially presenting as breast metastasis mimicking an abscess.
Full article available to subscribers
Large cell neuroendocrine carcinoma (LCNEC) is a rare and exceedingly aggressive high-grade cancer. This is a subtype of neuroendocrine carcinoma, which commonly originates in the lung but may arise in other organs, including the gastrointestinal tract and pancreas.1 This is heavily associated with smoking and typically affects males with a median age of around 65 years.2
Common sites of metastasis include the liver, bone, brain and adrenal glands.3 Metastatic involvement, from any primary, of the breast is rare.4 It has been estimated that only 0.005–0.02% of breast malignancies represent metastases from neuroendocrine tumours.5 Reported cases have typically presented as breast masses or nodules.5–7
This case illustrates an unusual presentation of LCNEC, initially presenting as breast metastasis mimicking an abscess.
A 38-year-old previously well, non-lactational, non-smoking female patient presented with a painful 5×5cm erythematous lump in the lower outer quadrant of the left breast. This was indurated, firm and mobile. She was otherwise clinically well, with no constitutional symptoms. An abscess was suspected by the emergency department team, and she was discharged with antibiotics.
One week later, she re-presented due to persistent symptoms and failure to improve on antibiotics. She was referred to general surgery. The abscess was surgically treated, and cavity biopsies were taken due to the intraoperative finding of a hard lesion with central necrosis, suspicious for malignancy.
Histological examination demonstrated features consistent with metastatic LCNEC of unknown primary origin. Tumour markers were markedly elevated, including chromogranin A, cancer antigen (CA) 15-3, CA 19-9, CA 125 and carcinoembryonic antigen.
During subsequent assessment, the patient was admitted with significant back pain. Computed tomography of the chest, abdomen and pelvis demonstrated an extensive malignant spread, including a large left upper lobe mass, with nodal, skeletal, pelvic and possible hepatic metastases; however, the primary tumour was not identified (Figure 1). Magnetic resonance imaging (MRI) confirmed lumbar spinal involvement (Figure 2).
View Figure 1–2.
This case was discussed at the neuroendocrine tumour multidisciplinary meeting, favouring the diagnosis of stage IVB LCNEC, most likely of lung origin, with widespread metastases.
Breast abscess is a common benign condition that is frequently managed by general surgeons.8 To our knowledge, presentation of neuroendocrine carcinoma as a breast abscess has not previously been reported. Awareness of this presentation is important, as metastases from neuroendocrine tumours to the breast may be more common than previously recognised.6
Management guidelines for LCNEC remain limited due to the rarity of the disease. Surgical resection is recommended for early-stage disease when feasible, while advanced disease is typically treated with platinum-based chemotherapy similar to that used for small cell lung cancer. The prognosis remains poor.9
Another notable feature of this case was the patient’s clinical profile. LCNEC is strongly associated with tobacco exposure, and its occurrence in a young lifelong non-smoker, as observed in this case, is uncommon.
Interestingly, molecular testing demonstrated an anaplastic lymphoma kinase rearrangement, a finding most commonly associated with lung adenocarcinoma and rarely reported in LCNEC.10 In this case, palliative radiotherapy for symptomatic spinal metastases was completed, and the patient was initially waitlisted to commence systemic chemotherapy with carboplatin and paclitaxel. However, after identifying this molecular alteration, targeted therapy with alectinib was commenced.
This case highlights an unusual presentation of metastatic LCNEC. It emphasises the importance of considering malignancy in the differential diagnosis of an apparently benign breast infection, and the necessity of high clinical suspicion in abscesses that are refractory to treatment.
Ally Yu: Medical Student, The University of Auckland, Auckland, New Zealand.
Dr Yijiao Wang (also known as Joanna): Registrar, Department of General Surgery, Health New Zealand – Te Whatu Ora Waitematā, Auckland, New Zealand.
Dr Eva S Juhasz: Colorectal and Breast Surgeon, Department of General Surgery, Health New Zealand – Te Whatu Ora Waitematā, Auckland, New Zealand.
We would like to thank the patient for providing us with her consent to write this case report.
Dr Yijiao (Joanna) Wang: Department of General Surgery, North Shore Hospital, 124 Shakespeare Road, Takapuna, Auckland, 0620. Ph: 09 486 8900
Nil.
1) Cuthbertson DJ, Shankland R, Srirajaskanthan R. Diagnosis and management of neuroendocrine tumours. Clin Med (Lond). 2023;23(2):119-124. doi: 10.7861/clinmed.2023-0044.
2) Andrini E, Marchese PV, De Biase D, et al. Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges. J Clin Med. 2022;11(5):1461. doi: 10.3390/jcm11051461.
3) Derks JL, Leblay N, Thunnissen E, et al. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Clin Cancer Res. 2018;24(1):33-42. doi: 10.1158/1078-0432.CCR-17-1921.
4) Aricò FM, Portaluri A, Catanzariti F, et al. Neuroendocrine Tumor Metastases to the Breast Mimic Breast Primary Carcinoma: Mammography and Multimodality US Assessment in Challenging Differential Diagnosis. Diagnostics (Basel). 2025;15(7):860. doi: 10.3390/diagnostics15070860.
5) Urrego Díaz JA, González M, Romero-Rojas AE, et al. Neuroendocrine Tumor Metastases to the Breast: A Case Report and Review of the Literature. Cureus. 2023;15(6):e40703. doi: 10.7759/cureus.40703.
6) Crona J, Granberg D, Norlén O, et al. Metastases from neuroendocrine tumors to the breast are more common than previously thought. A diagnostic pitfall? World J Surg. 2013;37(7):1701-1706. doi: 10.1007/s00268-013-2037-2.
7) Jiménez P, Urrego J, Ortiz-Llinás J, et al. Metastatic neuroendocrine neoplasms of the breast: a systematic review. Endocr Relat Cancer. 2025;32(12):e250109. doi: 10.1530/ERC-25-0109.
8) Gollapalli V, Liao J, Dudakovic A, et al. Risk factors for development and recurrence of primary breast abscesses. J Am Coll Surg. 2010;211(1):41-48. doi: 10.1016/j.jamcollsurg.2010.04.007.
9) Fasano M, Della Corte CM, Papaccio F, et al. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. J Thorac Oncol. 2015;10(8):1133-1141. doi: 10.1097/JTO.0000000000000589.
10) Hayashi N, Fujita A, Saikai T, et al. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib. Intern Med. 2018;57(5):713-716. doi: 10.2169/internalmedicine.9368-17.
Sign in to view your account and access
the latest publications by the NZMJ.
Don't have an account?
Let's get started with creating an account.
Already have an account?
Become a member to enjoy unlimited digital access and support the ongoing publication of the New Zealand Medical Journal.
The New Zealand Medical Journal is fully available to individual subscribers and does not incur a subscription fee. This applies to both New Zealand and international subscribers. Institutions are encouraged to subscribe. The value of institutional subscriptions is essential to the NZMJ, as supporting a reputable medical journal demonstrates an institution’s commitment to academic excellence and professional development. By continuing to pay for a subscription, institutions signal their support for valuable medical research and contribute to the journal's continued success.
Please email us at nzmj@pmagroup.co.nz